CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Regeneron Pharmaceuticals, Inc.

Ross Kenyon, P.E., Associate Director, Modeling, Simulation and Analysis, Regeneron Pharmaceuticals

Setting A Culture for Digital Transformation in the Biopharmaceutical Industry

Ross Kenyon

Ross Kenyon

Think for a moment about the phrase “digital transformation,” and what it really means to transform something. We are working to change fundamental elements of our business and do something that has not been done before. There are historically well-known challenges that come with any transformation: one is the simple act of embarking on an exploration of the unknown. Another is the uncomfortable reality of having to leave something behind. There may be courageous individuals who can confidently face both head winds but taken collectively, we fear the unknown and we are resistant to change.So how do we make our people comfortable, keep them motivated to succeed, and still conduct this transition efficiently?


Computational simulation is a key element of any biopharmaceutical company’s digital transformation effort, and I like to think of it as two distinct phases of work that are inherently connected: first is the process of developing credible models, and second is the integration of those models into business unit operations.


Developing models for biologics requires a close network of technical experts working together in a multi-disciplinary harmony. Mechanistic elements of a model are based on fluid dynamics, chemistry, and biology while empirical elements are driven by mathematics and data science.To be successful, these groups need to function in such a way that they build on each other’s work without feeling a sense of competition. Implementing the models requires a coordinated effort across multiple functional groups built on support from the IT organization.There is a web of connections that become established between the individuals undertaking this work as well as the business units of which they are a part.


The underlying enabler to this process is trust and security, and it needs to start at the top of the organization. Senior leadership must make it a top priority to establish a culture of psychological safety. 


Unless individuals feel a sense of trust, they are reluctant to share knowledge and train others. And if they are not secure enough to feel vulnerable, they will not inquire openly about what they do not know. One way to foster this culture is to design incentive structures that reinforce knowledge sharing and refocus recognition schemes. Most recognition schemes reward achievement against a milestone - what was done–but greater success can be realized by shifting emphasis to exemplary behaviors –how something was done. 


It becomes critical that the business is designed to encourage the information to flow and ensure it is readily available to all


Talent development is another key aspect, and it is not as simple as ushering in a new, digitally literate workforce. Everyone needs to develop digital capabilities and the knowledge must extend to every part of the business. Starting with a foundation of psychological safety and setting the tone for knowledge sharing, people become comfortable with curiosity and building a learning culture becomes a straightforward process.


Technical innovation, knowledge transfer and talent development are not linear processes, and they are dependent on the flow of information. So, it becomes critical that the business is designed to encourage the information to flow and ensure it is readily available to all. Think about how network effects function in a digital service – where the value of the service increases exponentially with the number of users or nodes. By increasing and improving communication, the business process itself can evolve to benefit from network effects. We just need to set the right conditions for this to happen.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/setting-a-culture-for-digital-transformation-in-the-biopharmaceutical-industry-nwid-913.html